Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Hinge Health Inc. Class A Common StockTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Hinge Health Inc. Class A Common Stock vs Oxford Lane Capital Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Oxford Lane Capital Corp trades at $8.22 (market cap $817.57M). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 10.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.78% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Oxford Lane Capital Corp for 51 Days on average.

HNGEOXLC
Market Cap
$8.48B$817.57M
Volume
879,7992,300,089
Sector
HealthFinancials
52-Week High
$105.14$16.02
52-Week Low
$31.17$8.15
Typical Hold Time
0 Days51 Days
Enterprise Value
$8.10B$1.21B
Dividend Yield
—28.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hinge Health Inc. Class A Common Stock

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Oxford Lane Capital Corp

OXLC trades at $8.34, down 3.02% on the day, with a bearish technical outlook and weak earnings performance. Recent quarters show significant EPS misses, including a -$6.23 actual versus $2.26 expected in Q1 2026. The company maintains a high dividend payout of $0.20 monthly, but negative ROE and ROA highlight profitability challenges. Net asset value updates indicate substantial unrealized losses, with revenue turning negative in 2026.

The outlook is cautious due to deteriorating fundamentals and high payout ratios exceeding sustainable levels. Investment opportunities exist for yield-seeking investors attracted to the deep discount to NAV, but risks include persistent earnings volatility, reliance on financing for cash flow, and competitive pressures in the CLO space. Analyst sentiment is mixed, with 50% buy ratings offset by bearish technical signals.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HNGE
100% Buy0% Sell
Avg holding period · 0 Days
OXLC
100% Buy0% Sell
Avg holding period · 51 Days

Top news

Latest headlines on both assets

About Hinge Health Inc. Class A Common Stock

Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.

Read more on HNGE →

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC →